Intralesional BO-112 Emerges as Nonsurgical Option for High-Risk BCC
Intralesional BO-112, a TLR agonist, shows early promise as a nonsurgical treatment for high-risk basal cell carcinoma, Dermatology Times reports.
Topic
High Risk Bcc
Topic
Topic
Topic
Intralesional BO-112, a TLR agonist, shows early promise as a nonsurgical treatment for high-risk basal cell carcinoma, Dermatology Times reports.